VANCOUVER, BC, Nov. 10, 2022 /CNW/ – Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) (“Filament” or the “Company”), a clinical-stage natural psychedelic drug development company, released its second quarter financial results and operational highlights for the period ended September 30, 2022. “Our third quarter demonstrated Filament’s continued progress both internally and externally,”…


Previous articleHealthline – Mental Health Breakthrough: The Therapeutic Benefits of Psychedelics
Next articlePT372 – The Heroic Hearts Project: Veterans and The Impact of Storytelling